评估4Kscore四激肽释放酶组合在Canary前列腺主动监测研究中预测高级别前列腺癌的价值
研究纳入718名多机构Canary PASS前瞻性试验中主动监测男性,在首次及后续监测活检前采集血浆,评估四激肽释放酶(4K)组合预测高级别癌的价值。活检数据按2:1分为训练集和测试集,建立含临床信息及4K组合或PSA的统计模型。首次活检时4K组合较基础模型提高预测准确性(AUC 0.78 vs 0.74),后续活检两模型表现相当(AUC 0.75 vs 0.76)。
要点
- 4K组合在首次监测活检时较基础模型提高预测重新分级的准确性(AUC 0.78 vs 0.74)。
- 后续监测活检时4K组合未较基础模型增加预测价值(AUC 0.75 vs 0.76)。
- 决策曲线分析中两模型净获益均高于全部活检和无活检策略。
核心结论
- 4K组合在诊断后首次活检时较常规临床信息对预测高级别癌提供增量价值。
- 4K组合在后续监测活检时未较基础模型增加预测价值。
研究设计与样本
- 研究为多机构Canary PASS前瞻性试验,纳入718名男性,在首次及后续监测活检前采集血浆。
- 活检数据按2:1分为训练集和测试集,建立含临床信息及4K组合或血清PSA的统计模型。
- 终点为重新分级至Gleason≥7,采用ROC曲线及AUC评估区分能力,决策曲线分析报告临床净获益。
主要发现
- 重新分级的显著预测因素包括4K组合(OR 1.54,95%CI 1.31-1.81)或PSA(OR 2.11,95%CI 1.53-2.91)。
- ≥20%穿刺针阳性(OR 2.10,95%CI 1.33-3.32)、既往≥2次阴性活检(OR 0.19,95%CI 0.04-0.85)、前列腺体积(OR 0.47,95%CI 0.31-0.70)及体重指数(OR 1.09,95%CI 1.04-1.14)亦为显著预测因素。
- 首次监测活检时4K组合较基础模型提高预测重新分级的准确性(AUC 0.78 vs 0.74)。
- 后续活检时两模型预测重新分级表现相当(AUC 0.75 vs 0.76)。
- 决策曲线分析中两模型净获益均高于全部活检和无活检策略。
临床怎么用
- 作者认为4K组合在诊断后首次活检时较常规临床信息对预测高级别癌提供增量价值。
- 作者认为4K组合在后续监测活检时未较基础模型增加预测价值。
- 原文指出结果应在另一队列中验证后方可用于临床。
局限性
- 局限性包括研究的单队列性质和小样本量。
- 结果应在另一队列中验证后方可用于临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diagnosis of Gleason 6 prostate cancer can leave uncertainty about the presence of undetected aggressive disease. OBJECTIVE: To evaluate the utility of a four kallikrein (4K) panel in predicting the presence of high-grade cancer in men on active surveillance. DESIGN, SETTING, AND PARTICIPANTS: Plasma collected before the first and subsequent surveillance biopsies was assessed for 718 men prospectively enrolled in the multi-institutional Canary PASS trial. Biopsy data were split 2:1 into training and test sets. We developed statistical models that included clinical information and either the 4Kpanel or serum prostate-specific antigen (PSA). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The endpoint was reclassification to Gleason ≥7. We used receiver operating characteristic (ROC) curve analyses and area under the curve (AUC) to assess discriminatory capacity, and decision curve analysis (DCA) to report clinical net benefit. RESULTS AND LIMITATIONS: Significant predictors for reclassification were 4Kpanel (odds ratio [OR] 1.54, 95% confidence interval [CI] 1.31-1.81) or PSA (OR 2.11, 95% CI 1.53-2.91), ≥20% cores positive (OR 2.10, 95% CI 1.33-3.32), two or more prior negative biopsies (OR 0.19, 95% CI 0.04-0.85), prostate volume (OR 0.47, 95% CI 0.31-0.70), and body mass index (OR 1.09, 95% CI 1.04-1.14). ROC curve analysis comparing 4K and base models indicated that the 4Kpanel improved accuracy for predicting reclassification (AUC 0.78 vs 0.74) at the first surveillance biopsy. Both models performed comparably for prediction of reclassification at subsequent biopsies (AUC 0.75 vs 0.76). In DCA, both models showed higher net benefit compared to biopsy-all and biopsy-none strategies. Limitations include the single cohort nature of the study and the small numbers; results should be validated in another cohort before clinical use. CONCLUSIONS: The 4Kpanel provided incremental value over routine clinical information in predicting high-grade cancer in the first biopsy after diagnosis. The 4Kpanel did not add predictive value to the base model at subsequent surveillance biopsies. PATIENT SUMMARY: Active surveillance is a management strategy for many low-grade prostate cancers. Repeat biopsies monitor for previously undetected high-grade cancer. We show that a model with clinical variables, including a panel of four kallikreins, indicates the presence of high-grade cancer before a biopsy is performed.
引用
- Lin DW, Newcomb LF, Brown MD, et al. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Eur Urol. 2016. PMID: 27889277. doi:10.1016/j.eururo.2016.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。